Will CBCa (cannabichromenic acid) and CBC (cannabichromene) be the next hot commercial cannabinoids? If based just on medical benefits, quite likely. A peer cannabinoid of THCa and CBDa, CBCa also is converted from CBGa via a CBC synthase.
Besides being an anti-inflammatory, it appears to work wonders for what could be the next scourge of mankind caused by Big Pharma: antibiotic-resistant staph infection (MRSA), often found in hospitals. It’s a selective CB2 agonist like the terpene beta-caryophyllene, more efficient than THC there. THC enhances CBC’s effect.
A review of CBC-rich seed vendors reveals it’s more a marijuana cannabinoid, than hemp. There is a patent on one variety. Front Range Biosciences, and Wulf Hemp purportedly have CBD-rich seed. If THC-dominant varieties are Type 1, and 1:1 are Type 2, and CBD-dominant are Type 3, and CBG-dominant are Type 4, and nil cannabinoid varieties are Type 5, perhaps CBC-dominant should be called Type 6?
A search of CannLib v2.3 for Cannabichromene OR “Cannabichromenic Acid” results in 558 files 1.03 gB in size total, 2,027 total hits, most hits: Handbook of Cannabis (Roger Pertwee, 2014): 58 hits, and Biological Activity of Cannabichromenes, Homologs and Isomers (Turner and ElSohly, 1980): 56 hits.
Antibiotics, Aug 16 2020;9(8):523.
Methicillin-resistant Staphylococcus aureus (MRSA) has proven to be an imminent threat to public health, intensifying the need for novel therapeutics. Previous evidence suggests that cannabinoids harbour potent antibacterial activity. In this study, a group of previously inaccessible phytocannabinoids and synthetic analogues were examined for potential antibacterial activity. The minimum inhibitory concentrations and dynamics of bacterial inhibition, determined through resazurin reduction and time-kill assays, revealed the potent antibacterial activity of the phytocannabinoids against gram-positive antibiotic-resistant bacterial species, including MRSA. One phytocannabinoid, cannabichromenic acid (CBCA), demonstrated faster and more potent bactericidal activity than vancomycin, the currently recommended antibiotic for the treatment of MRSA infections. Such bactericidal activity was sustained against low-and high-dose inoculums as well as exponential- and stationary-phase MRSA cells. Further, mammalian cell viability was maintained in the presence of CBCA. Finally, microscopic evaluation suggests that CBCA may function through the degradation of the bacterial lipid membrane and alteration of the bacterial nucleoid. The results of the current study provide encouraging evidence that cannabinoids may serve as a previously unrecognised resource for the generation of novel antibiotics active against MRSA.”